Abstract
Background Asthma diagnosis in the community is often made without objective testing.
Objective The aim of this study was to evaluate the cost-effectiveness of implementing a stepwise objective diagnostic verification algorithm among patients with community-diagnosed asthma in the United States (US).
Methods We developed a probabilistic time-in-state cohort model that compared a stepwise asthma verification algorithm based on spirometry and methacholine challenge test against the current standard of care over 20 years. Model input parameters were informed from the literature and with original data analyses when required. The target population was US adults (≥15 y/o) with physician-diagnosed asthma. The final outcomes were costs (in 2018 $) and quality-adjusted life years (QALYs), discounted at 3% annually. Deterministic and probabilistic analyses were undertaken to examine the effect of alternative assumptions and uncertainty in model parameters on the results.
Results In a simulated cohort of 10,000 adults with diagnosed asthma, the stepwise algorithm resulted in the removal of diagnosis in 3,366. This was projected to be associated with savings of $36.26 million in direct costs and a gain of 4,049.28 QALYs over 20 years. Extrapolating these results to the US population indicated an undiscounted potential savings of $56.48 billion over 20 years. Results were robust against alternative assumptions and plausible changes in values of input parameters.
Conclusion Implementation of a simple diagnostic testing algorithm to verify asthma diagnosis might result in substantial savings and improvement in patients’ quality of life.
Key Messages
Compared with current standards of practice, the implementation of an asthma verification algorithm among US adults with diagnosed asthma can be associated with reduction in costs and gain in quality of life.
There is substantial room for improving patient care and outcomes through promoting objective asthma diagnosis.
Capsule summary Asthma ‘overdiagnosis’ is common among US adults. An objective, stepwise verification algorithm for re-evaluation of asthma diagnosis can result in substantial savings in costs and improvements in quality of life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by an independent research contract by MethaPharm Inc. (Brantford, Ontario, Canada). The sponsor is aware of the content of the submitted material but neither played any role nor exerted any influence in the design of the study, conduct of the research, or reporting of the results.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of support: This study was funded by an independent research contract by MethaPharm Inc. (Brantford, Ontario, Canada). The sponsor is aware of the content of the submitted material but neither played any role nor exerted any influence in the design of the study, conduct of the research, or reporting of the results.
Data Availability
This is a simulation study so there are no underlying data. One part of the study was based on data from the Medical Expenditure Panel Survey in the US. Eligible clients can apply for such data through the relevant portal.
https://drive.google.com/file/d/1pd2e9qEa6nIMV9UpCPX4mI2SUTaUr9Yw/view?usp=sharing
Abbreviations
- ACT
- Asthma Control Test
- FEV1
- Forced Expiratory Volume
- GBD
- Global Burden of Disease
- GINA
- Global Initiative for Asthma
- ICER
- Incremental Cost Effectiveness Ratio
- ICS
- Inhaled Corticosteroids
- LTRA
- Leukotriene receptor antagonist therapy
- MCT
- Methacholine Challenge Test (Bronchoprovocation Test)
- OR
- Odds Ratio
- PC20
- The concentration of methacholine needed to produce a 20% fall in FEV1
- QALY
- Quality Adjusted Life Year
- US
- United States